Drug updated on 11/13/2023
|Tablet (oral:150 mg)
|Ongoing and Completed Studies
- For the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Product Monograph / Prescribing Information
|Zykadia (ceritinib) Prescribing Information.
|Novartis Pharmaceuticals Corporation, East Hanover, NJ
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Therapy for stage iv non–small-cell lung cancer with driver alterations: asco living guideline.
|Journal of Clinical Oncology
|Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group.
|Journal of the National Cancer Center
|Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
|Annals of Oncology
|Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology.
|Journal of the National Comprehensive Cancer Network